At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KOD Kodiak Sciences Inc.
Trading 10-22 15:03:42 EDT
85.72
-2.00
-2.28%
High89.52Low85.02Vol344.49K
Open87.14D1 Closing87.72Amplitude5.13%
Mkt Cap5.36BTradable Cap3.17BTotal Shares62.58M
T/O29.81MT/O Rate0.93%Tradable Shares36.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Kodiak Sciences Inc. Intraday Decline 5.01%, Prior Phase 3 eye-data progress and director buying remain in focus
Market Focus  ·  10-22 02:51
Movement Alert｜Kodiak Sciences Inc. Intraday Decline 5.01%, Prior Phase 3 eye-data progress and director buying remain in focus
Kodiak Sciences Inc.: May Offer up to $350 Mln Common Stock Under Distribution Agreement with J.p. Morgan - SEC Filing
THOMSON REUTERS  ·  10-21 05:19
Kodiak Sciences Inc.: May Offer up to $350 Mln Common Stock Under Distribution Agreement with J.p. Morgan - SEC Filing
Kodiak Sciences Inc.: Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  10-21 05:19
Kodiak Sciences Inc.: Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 5.11% in Regular Trading, Phase 3 eye-drug progress and large insider buying remain in focus
Market Focus  ·  10-20 23:31
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 5.11% in Regular Trading, Phase 3 eye-drug progress and large insider buying remain in focus
Movement Alert｜Kodiak Sciences Inc. Overnight Rise 5.07%, Phase 3 eye-drug progress and major director share purchase remain in focus
Market Focus  ·  10-20 14:17
Movement Alert｜Kodiak Sciences Inc. Overnight Rise 5.07%, Phase 3 eye-drug progress and major director share purchase remain in focus
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 6.27% in Regular Trading, Phase 3 eye-drug progress and major insider buying remain in focus
Market Focus  ·  10-20
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 6.27% in Regular Trading, Phase 3 eye-drug progress and major insider buying remain in focus
Kodiak Sciences (KOD), What Is Behind The Latest Move?
Simply Wall St.  ·  10-16
Kodiak Sciences (KOD), What Is Behind The Latest Move?
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 5.2% in Regular Trading, Phase 3 eye-drug progress and large insider buying remain in focus
Market Focus  ·  10-16
Movement Alert｜Kodiak Sciences Inc. Intraday Rise 5.2% in Regular Trading, Phase 3 eye-drug progress and large insider buying remain in focus
Kodiak Sciences put volume heavy and directionally bearish
TIPRANKS  ·  10-15
Kodiak Sciences put volume heavy and directionally bearish
Movement Alert｜Kodiak Sciences Inc. Falls 5.6% in Regular Trading, Earlier Insider Buying Tailwind Loses Momentum
Market Focus  ·  10-14
Movement Alert｜Kodiak Sciences Inc. Falls 5.6% in Regular Trading, Earlier Insider Buying Tailwind Loses Momentum
Canaccord Genuity Reaffirms Their Buy Rating on Kodal Minerals (KOD)
TIPRANKS  ·  10-14
Canaccord Genuity Reaffirms Their Buy Rating on Kodal Minerals (KOD)
Movement Alert｜Kodiak Sciences Inc. Falls 5.03% in Regular Trading, Insider Buying Boost Shows Signs of Fading
Market Focus  ·  10-14
Movement Alert｜Kodiak Sciences Inc. Falls 5.03% in Regular Trading, Insider Buying Boost Shows Signs of Fading
Kodiak Sciences Price Target Raised to $126.00/Share from $96.00 by HC Wainwright & Co.
Dow Jones  ·  10-12
Kodiak Sciences Price Target Raised to $126.00/Share from $96.00 by HC Wainwright & Co.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)
TIPRANKS  ·  10-12
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)
Movement Alert｜Kodiak Sciences Inc. Rises 5.63% in Regular Trading, Insider Buying Reinforces Market Confidence After Phase 3 Success
Market Focus  ·  10-09
Movement Alert｜Kodiak Sciences Inc. Rises 5.63% in Regular Trading, Insider Buying Reinforces Market Confidence After Phase 3 Success
Kodiak Sciences to Present Phase 3 Daybreak Wet AMD Data for Zenkuda at AAO 2026
Reuters  ·  10-07
Kodiak Sciences to Present Phase 3 Daybreak Wet AMD Data for Zenkuda at AAO 2026
Kodiak Sciences Stock Pick of the Week at Smart Insider Following Insider Share Purchase
MT Newswires Live  ·  10-06
Kodiak Sciences Stock Pick of the Week at Smart Insider Following Insider Share Purchase
Movement Alert｜Kodiak Sciences Inc. Intraday Decline 5.09%, Profit-Taking Pressure Emerges After Key Data Release
Market Focus  ·  10-05
Movement Alert｜Kodiak Sciences Inc. Intraday Decline 5.09%, Profit-Taking Pressure Emerges After Key Data Release
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
TIPRANKS  ·  10-05
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
Movement Alert｜Kodiak Sciences Inc. Declines 5.08% in Regular Trading, Trading at $93.76
Market Focus  ·  10-02
Movement Alert｜Kodiak Sciences Inc. Declines 5.08% in Regular Trading, Trading at $93.76

Introduction

Company Name.
Kodiak Sciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Issue price:
--